SEARCH

SEARCH BY CITATION

References

  • Aalto-Setala K., Fisher E. A., Chen X. et al. (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90, 18891900.
  • Abildayeva K., Jansen P. J., Hirsch-Reinshagen V. et al. (2006) 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281, 1279912808.
  • Adams C. M., Reitz J., De Brabander J. K., Feramisco J. D., Li L., Brown M. S. and Goldstein J. L. (2004) Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J. Biol. Chem. 279, 5277252780.
  • Adunsky A., Chesnin V., Davidson M., Gerber Y., Alexander K. and Haratz D. (2002) A cross-sectional study of lipids and ApoC levels in Alzheimer’s patients with and without cardiovascular disease. J. Gerontol. A Biol. Sci. Med. Sci. 57, M757M761.
  • Akanuma S., Hori S., Ohtsuki S., Fujiyoshi M. and Terasaki T. (2008) Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood–brain barrier. Neurochem. Int. 52, 669674.
  • Alafuzoff I., Adolfsson R., Bucht G. and Winblad B. (1983) Albumin and immunoglobulin in plasma and cerebrospinal fluid, blood–cerebrospinal fluid barrier function in patients with dementia of Alzhiemer type and multi-infarct dementia. J. Neurol. Sci. 60, 465472.
  • Andrieu-Abadie N., Gouaze V., Salvayre R. and Levade T. (2001) Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic. Biol. Med. 31, 717728.
  • Arispe N. (2004) Architecture of the Alzheimer’s A beta P ion channel pore. J. Membr. Biol. 197, 3348.
  • Arispe N., Pollard H. B. and Rojas E. (1993) Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl Acad. Sci. USA 90, 1057310577.
  • Von Arnim C. A., Kinoshita A., Peltan I. D. et al. (2005) The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J. Biol. Chem. 280, 1777717785.
  • Von Arnim C. A., Von Einem B., Weber P., Wagner M., Schwanzar D., Spoelgen R., Strauss W. L. and Schneckenburger H. (2008) Impact of cholesterol level upon APP and BACE proximity and APP cleavage. Biochem. Biophys. Res. Commun. 370, 207212.
  • Austen B., Christodoulou G. and Terry J. E. (2002) Relation between cholesterol levels, statins and Alzheimer’s disease in the human population. J. Nutr. Health Aging 6, 377382.
  • Balazs Z., Panzenboeck U., Hammer A., Sovic A., Quehenberger O., Malle E. and Sattler W. (2004) Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood–brain barrier model. J. Neurochem. 89, 939950.
  • Bales K. R., Verina T., Cummins D. J. et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 96, 1523315238.
  • Ballabh P., Braun A. and Nedergaard M. (2004) The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 113.
  • Bandaru V. V., Troncoso J., Wheeler D., Pletnikova O., Wang J., Conant K. and Haughey N. J. (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiol. Aging 30, 591599.
  • Barnham K. J., Masters C. L. and Bush A. I. (2004) Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3, 205214.
  • Bassett C., Montine K., Neely M., Swift L. and Montine T. (2000) Cerebrospinal fluid lipoproteins in Alzheimer’s disease. Micros. Res. Tech. 50, 282286.
  • Baum L., Chen L., Masliah E., Chan Y. S., Ng H. K. and Pang C. P. (1999) Lipoprotein lipase mutations and Alzheimer’s disease. Am. J. Med. Genet. 88, 136139.
  • Begley D. J. (2004) ABC transporters and the blood–brain barrier. Curr. Pharm. Des. 10, 12951312.
  • Bell R. D., Sagare A. P., Friedman A. E., Bedi G. S., Holtzman D. M., Deane R. and Zlokovic B. V. (2007) Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27, 909918.
  • Belloir B., Kovari E., Surini-Demiri M. and Savioz A. (2001) Altered apolipoprotein D expression in the brain of patients with Alzheimer disease. J. Neurosci. Res. 64, 6169.
  • Bereczki E., Bernat G., Csont T., Ferdinandy P., Scheich H. and Santha M. (2008) Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J. Proteome Res. 7, 22462252.
  • Bertram L., Hsiao M., McQueen M. B., Parkinson M., Mullin K., Blacker D. and Tanzi R. E. (2007) The LDLR locus in Alzheimer's disease: a family-based study and meta-analysis of case-control data. Neurobiol. Aging 28, 18 e1114.
  • Bismuth J., Lin P., Yao Q. and Chen C. (2008) Ceramide: a common pathway for atherosclerosis? Atherosclerosis 196, 497504.
  • Bjelik A., Bereczki E., Gonda S. et al. (2006) Human apoB overexpression and a high-cholesterol diet differently modify the brain APP metabolism in the transgenic mouse model of atherosclerosis. Neurochem. Int. 49, 393400.
  • Bjorkhem I. and Meaney S. (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24, 806815.
  • Bjorkhem I., Lutjohann D., Breuer O., Sakinis A. and Wennmalm A. (1997) Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J. Biol. Chem. 272, 3017830184.
  • Bjorkhem I., Lutjohann D., Diczfalusy U., Stahle L., Ahlborg G. and Wahren J. (1998) Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39, 15941600.
  • Bjorkhem I., Diczfalusy U. and Lutjohann D. (1999) Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr. Opin. Lipidol. 10, 161165.
  • Bjorkhem I., Heverin M., Leoni V., Meaney S. and Diczfalusy U. (2006) Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. Suppl. 185, 4349.
  • Blain J. F., Aumont N., Theroux L., Dea D. and Poirier J. (2006) A polymorphism in lipoprotein lipase affects the severity of Alzheimer’s disease pathophysiology. Eur. J. Neurosci. 24, 12451251.
  • Blennow K., Wallin A., Fredman P., Karlsson I., Gottfries C. G. and Svennerholm L. (1990) Blood–brain barrier disturbance in patients with Alzheimer’s disease is related to vascular factors. Acta Neurol. Scand. 81, 323326.
  • Boggs L. N., Fuson K. S., Baez M., Churgay L., McClure D., Becker G. and May P. C. (1996) Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J. Neurochem. 67, 13241327.
  • Boisfer E., Lambert G., Atger V. et al. (1999) Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 274, 1156411572.
  • Borghini I., Barja F., Pometta D. and James R. W. (1995) Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim. Biophys. Acta 1255, 192200.
  • Borroni B., Archetti S., Agosti C., Akkawi N., Brambilla C., Caimi L., Caltagirone C., Di Luca M. and Padovani A. (2004) Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators. Neurobiol. Aging 25, 747751.
  • Bowden K. and Ridgway N. D. (2008) OSBP negatively regulates ABCA1 protein stability. J. Biol. Chem. 283, 1821018217.
  • Boyles J. K., Pitas R. E., Wilson E., Mahley R. W. and Taylor J. M. (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76, 15011513.
  • Brahimi F., Bertrand P., Starck M., Galteau M. M. and Siest G. (2001) Control of apolipoprotein E secretion in the human hepatoma cell line KYN-2. Cell Biochem. Funct. 19, 5158.
  • Breckenridge W. C., Little J. A., Steiner G., Chow A. and Poapst M. (1978) Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N. Engl. J. Med. 298, 12651273.
  • Brody T. (1999) Nutritional Biochemistry. Academic Press, San Diego.
  • Brooksbank B. W. and McGovern J. (1989) Gangliosides in the brain in adult Down’s syndrome and Alzheimer’s disease. Mol. Chem. Neuropathol. 11, 143156.
  • Brown M. S. and Goldstein J. L. (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331340.
  • Brown D. A. and London E. (2000) Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275, 1722117224.
  • Bu G., Cam J. and Zerbinatti C. V. (2006) LRP in amyloid-beta; production and metabolism. Ann. N Y Acad. Sci. 1086, 3553.
  • Buclin T. and Biollaz J. (2005) [The blood–brain barrier: recent insights]. Rev Med Suisse 1, 959963.
  • Burgess B. L., McIsaac S. A., Naus K. E., Chan J. Y., Tansley G. H. K. and Yang J. (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer’s disease mouse models with abundant Aβ in plasma. Neurobiol. Dis. 24, 114127.
  • Burgess B. L., Parkinson P. F., Racke M. M. et al. (2008) ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49, 12541267.
  • Burns A., Byrne E. J. and Maurer K. (2002) Alzheimer’s disease. Lancet 360, 163165.
  • Butterfield D. A., Hensley K., Harris M., Mattson M. and Carney J. (1994) beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer’s disease. Biochem. Biophys. Res. Comm. 200, 710715.
  • Butterfield D. A., Griffin S., Munch G. and Pasinetti G. M. (2002) Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer’s disease brain exists. J. Alzheimers Dis. 4, 193201.
  • Buttini M., Yu G. Q., Shockley K. et al. (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 22, 1053910548.
  • Caballero J. and Nahata M. (2004) Do statins slow down Alzheimer’s disease? A review. J. Clin. Pharm. Ther. 29, 209213.
  • Caille I., Allinquant B., Dupont E., Bouillot C., Langer A., Muller U. and Prochiantz A. (2004) Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131, 21732181.
  • Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B. and Ghiso J. (2000) Apolipoprotein J (clusterin) and Alzheimer’s disease. Microsc. Res. Tech. 50, 305315.
  • Cam J. A. and Bu G. (2006) Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol. Neurodegener. 1, 8.
  • Cam J. A., Zerbinatti C. V., Knisely J. M., Hecimovic S., Li Y. and Bu G. (2004) The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J. Biol. Chem. 279, 2963929646.
  • Cao D., Fukuchi K., Hongquan W., Kim H. and Ling L. (2006) Lack of the LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol. Aging 27, 16321643.
  • Carter C. J. (2007) Convergence of genes implicated in Alzheimer’s disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 50, 1238.
  • Castellani L. W., Goto A. M. and Lusis A. J. (2001) Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes 50, 643651.
  • Cedazo-Minguez A. (2007) Apolipoprotein E and Alzheimer’s disease: molecular mechanisms and therapeutic opportunities. J. Cell Mol. Med. 11, 12271238.
  • Chan C.-W., Dharmarajan A., Atwood C. S., Huang X., Tanzi R. E., Bush A. I. and Martins R. N. (1999) Anti-apoptotic action of Alzheimer Aß. Alzheimer’s Rep. 2, 113119.
  • Chan S. L., Kim W. S., Kwok J. B., Hill A. F., Cappai R., Rye K. A. and Garner B. (2008) ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J. Neurochem. 106, 793804.
  • Chang J. Y., Phelan K. D. and Chavis J. A. (1998) Neurotoxicity of 25-OH-cholesterol on sympathetic neurons. Brain Res. Bull. 45, 615622.
  • Chauhan N. B., Siegel G. J. and Feinstein D. L. (2004) Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem. Res. 29, 18971911.
  • Chen D. W., Yang J. F., Tang Z., Dong X. M., Feng X. L., Yu S. and Chan P. (2008) Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer’s disease as a modifier for APOE epsilon4 in Chinese. Brain Res. 1187, 5257.
  • Cheng H., Vetrivel K. S., Gong P., Meckler X., Parent A. and Thinakaran G. (2007) Mechanisms of disease: new therapeutic strategies for Alzheimer’s disease--targeting APP processing in lipid rafts. Nat. Clin. Pract. Neurol. 3, 374382.
  • Chiesa G., Johnson D. F., Yao Z., Innerarity T. L., Mahley R. W., Young S. G., Hammer R. H. and Hobbs H. H. (1993) Expression of human apolipoprotein B100 in transgenic mice. Editing of human apolipoprotein B100 mRNA. J. Biol. Chem. 268, 2374723750.
  • Choi-Miura N. H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T. and Tomita M. (1992) SP-40,40 is a constituent of Alzheimer’s amyloid. Acta Neuropathol. 83, 260264.
  • Claudio L. (1996) Ultrastructural features of the blood–brain barrier in biopsy tissue from Alzheimer’s disease patients. Acta Neuropathol. 91, 614.
  • Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J. and Ashe K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 7984.
  • Cole S. L., Grudzien A., Manhart I. O., Kelly B. L., Oakley H. and Vassar R. (2005) Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J. Biol. Chem. 280, 1875518770.
  • Collet X., Francone O., Besnard F. and Fielding C. J. (1999) Secretion of lecithin:cholesterol acyl transferase by brain neurological cell lines. Biochim. Biophys. Res. Comm. 258, 7376.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921923.
  • Costet P., Luo Y., Wang N. and Tall A. R. (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275, 2824028245.
  • Crino P. B., Ullman M. D., Vogt B. A., Bird E. D. and Volicer L. (1989) Brain gangliosides in dementia of the Alzheimer type. Arch. Neurol. 46, 398401.
  • Cutler R. G., Haughey N. J., Tammara A., McArthur J. C., Nath A., Reid R., Vargas D. L., Pardo C. A. and Mattson M. P. (2004a) Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology 63, 626630.
  • Cutler R. G., Kelly J., Storie K., Pedersen W. A., Tammara A., Hatanpaa K., Troncoso J. C. and Mattson M. P. (2004b) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc. Natl Acad. Sci. U S A 101, 20702075.
  • D’Introno A., Solfrizzi V., Colacicco A. M., Capurso C., Torres F., Capurso S. A., Capurso A. and Panza F. (2005) Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer’s disease. J. Gerontol. A Biol. Sci. Med. Sci. 60, 280284.
  • Dahlgren K. N., Manelli A. M., Stine W. B. Jr, Baker L. K., Krafft G. A. and LaDu M. J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277, 3204632053. Epub 32002 Jun 32010.
  • Davignon J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39III43.
  • Davignon J. and Laaksonen R. (1999) Low-density lipoprotein-independent effects of statins. Curr. Opin. Lipidol. 10, 543559.
  • Dean M., Hamon Y. and Chimini G. (2001) The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42, 10071017.
  • Deane R., Wu Z., Sagare A. et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333344.
  • Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M. B., Holtzman D. M. and Zlokovic B. V. (2008a) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 40024013.
  • Deane R., Sagare A. and Zlokovic B. V. (2008b) The role of the cell surface LRP and soluble LRP in blood–brain barrier Abeta clearance in Alzheimer’s disease. Curr. Pharm. Des. 14, 16011605.
  • DeKosky S. T. (2005) Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am. J. Med. 118(Suppl. 12A), 4853.
  • Demeester N., Castro G., Desrumaux C., De Geitere C., Fruchart J. C. and Santens P. (2000) Characterization and functional studies of lipoproteins, lipid transfer proteins, lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer’s disease. J. Lipid Res. 41, 963974.
  • Desai P. P., Ikonomovic M. D., Abrahamson E. E., Hamilton R. L., Isanski B. A., Hope C. E., Klunk W. E., DeKosky S. T. and Kamboh M. I. (2005) Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer’s disease temporal cortex. Neurobiol. Dis. 20, 574582.
  • Dickson T. C., Saunders H. L. and Vickers J. C. (1997) Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 23, 483491.
  • Diczfalusy U., Olofsson K. E., Carlsson A. M., Gong M., Golenbock D. T., Rooyackers O., Flaring U. and Bjorkbacka H. (2009) Marked up-regulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J. Lipid Res. 50(11): 22582264.
  • Diedrich J. F., Minnigan H., Carp R. I., Whitaker J. N., Race R., Frey W. 2nd and Haase A. T. (1991) Neuropathological changes in scrapie and Alzheimer’s disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J. Virol. 65, 47594768.
  • Dieter M. Z., Maher J. M., Cheng X. and Klaassen C. D. (2004) Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 139, 209218.
  • Dietschy J. M. and Turley S. D. (2001) Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12, 105112.
  • Dietschy J. M. and Turley S. D. (2004) Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 13751397.
  • Distl R., Meske V. and Ohm T. G. (2001) Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol. 101, 547554.
  • Donahue J. E., Flaherty S. L., Johanson C. E. et al. (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 112, 405415.
  • Drayna D. T., McLean J. W., Wion K. L., Trent J. M., Drabkin H. A. and Lawn R. M. (1987) Human apolipoprotein D gene: gene sequence, chromosome localization, and homology to the alpha 2μ-globulin superfamily. DNA 6, 199204.
  • Drigalenko E., Poduslo S. and Elston R. (1998) Interaction of the apolipoprotein E and CI loci in predisposing to late-onset Alzheimer’s disease. Neurology 51, 131135.
  • Durell S., Guy H., Arispe N., Rojas E. and Pollard H. (1994) Theoretical models of the ion channel structure of amyloid-beta protein. Biophys. J. 67, 21372145.
  • Eberle D., Hegarty B., Bossard P., Ferre P. and Foufelle F. (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86, 839848.
  • Edmond J. (2001) Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J. Mol. Neurosci. 16, 181193.
  • Elshourbagy N. A., Liao W. S., Mahley R. W. and Taylor J. M. (1985) Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl Acad. Sci. USA 82, 203207.
  • Escola-Gil J. C., Julve J., Marzal-Casacuberta A., Ordonez-Llanos J., Gonzalez-Sastre F. and Blanco-Vaca F. (2001) ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J. Lipid Res. 42, 241248.
  • Fagan A. M. and Holtzman D. M. (2000) Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. Microsc. Res. Tech. 50, 297304.
  • Fagan A. M., Holtzman D. M., Munson G. et al. (1999) Unique lipoproteins secreted by primary astrocytes from wild type, apoE (−/−), and human apoE transgenic mice. J. Biol. Chem. 274, 3000130007.
  • Farooqui A. A., Ong W. Y., Horrocks L. A., Chen P. and Farooqui T. (2007) Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res. Rev. 56, 443471.
  • Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 58565861.
  • Ferri C. P., Prince M., Brayne C. et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 21122117.
  • Flower D. R. (1994) The lipocalin protein family: a role in cell regulation. FEBS Lett. 354, 711.
  • Funfschilling U., Saher G., Xiao L., Mobius W. and Nave K. A. (2007) Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci. 8, 1.
  • Galbete J. L., Rodriguez-Martin T., Peressini E., Modena P., Bianchi R. and Forloni G. (2000) Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J. 348, 307313.
  • Gandy S., Almeida O. P., Fonte J., Lim D., Waterrus A., Spry N., Flicker L. and Martins R. N. (2001) Chemical andropause and amyloid-beta peptide. JAMA 285, 21952196.
  • Ge S., Song L. and Pachter J. S. (2005) Where is the blood–brain barrier... really? J. Neurosci. Res. 79, 421427.
  • Gearing M., Schneider J. A., Robbins R. S., Hollister R. D., Mori H., Games D., Hyman B. T. and Mirra S. S. (1995) Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 54, 833841.
  • Gelissen I. C., Hochgrebe T., Wilson M. R., Easterbrook-Smith S. B., Jessup W., Dean R. T. and Brown A. J. (1998) Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem. J. 331, 231237.
  • Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T. and Frangione B. (1993) The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293, 2730.
  • Ginsberg H. N. (1998) Lipoprotein physiology. Endocrinol. Metab. Clin. North Am. 27, 503519.
  • Giovannoni M. P., Piaz V. D., Vergelli C. and Barlocco D. (2003) Selective ACAT inhibitors as promising antihyperlipidemic, antiathero-sclerotic and anti-Alzheimer drugs. Mini Rev. Med. Chem. 3, 576584.
  • Gorelick P. B. (2004) Risk factors for vascular dementia and Alzheimer disease. Stroke 35, 26202622.
  • Goti D., Balazs Z., Panzenboeck U., Hrzenjak A., Reicher H., Wagner E., Zechner R., Malle E. and Sattler W. (2002) Effects of lipoprotein lipase on uptake and transcytosis of low density lipoprotein (LDL) and LDL-associated alpha-tocopherol in a porcine in vitro blood–brain barrier model. J. Biol. Chem. 277, 2853728544.
  • Gotto A. M. Jr, Pownall H. J. and Havel R. J. (1986) Introduction to the plasma lipoproteins. Methods Enzymol. 128, 341.
  • Grimm M. O., Tschape J. A., Grimm H. S., Zinser E. G. and Hartmann T. (2006) Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurol. Scand. Suppl. 185, 2732.
  • Grimm M. O., Grimm H. S. and Hartmann T. (2007) Amyloid beta as a regulator of lipid homeostasis. Trends Mol. Med. 13, 337344.
  • Gueguen Y., Bertrand P., Ferrari L., Batt A. M. and Siest G. (2001) Control of apolipoprotein E secretion by 25-hydroxycholesterol and proinflammatory cytokines in the human astrocytoma cell line CCF-STTG1. Cell Biol. Toxicol. 17, 191199.
  • Hampel H., Muller-Spahn F., Berger C., Haberl A., Ackenheil M. and Hock C. (1995) Evidence of blood–cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 6, 348354.
  • Hampel H., Kotter H. U. and Moller H. J. (1997) Blood–cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Dis. Assoc. Disord. 11, 7887.
  • Han X. (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res 2, 6577.
  • Han X., Holtzman D., McKeel D. W. Jr, Kelley J. and Morris J. C. (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J. Neurochem. 82, 809818.
  • Harr S. D., Uint L., Hollister R., Hyman B. T. and Mendez A. J. (1996) Brain expression of apolipoproteins E, J, and A-I in Alzheimer’s disease. J. Neurochem. 66, 24292435.
  • Hayashi H., Campenot R. B., Vance D. E. and Vance J. E. (2004) Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J. Biol. Chem. 279, 1400914015.
  • Hedrick C. C., Castellani L. W., Warden C. H., Puppione D. L. and Lusis A. J. (1993) Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J. Biol. Chem. 268, 2067620682.
  • Helisalmi S., Hiltunen M., Vepsalainen S., Iivonen S., Corder E. H., Lehtovirta M., Mannermaa A., Koivisto A. M. and Soininen H. (2004) Genetic variation in apolipoprotein D and Alzheimer’s disease. J. Neurol. 251, 951957.
  • Herz J. (2003) LRP: a bright beacon at the blood–brain barrier. J. Clin. Invest. 112, 14831485.
  • Herz J. (2009) Apolipoprotein E receptors in the nervous system. Curr. Opin. Lipidol. 20, 190196.
  • Herz J. and Bock H. H. (2002) Lipoprotein receptors in the nervous system. Annu. Rev. Biochem. 71, 405434.
  • Heverin M., Bogdanovic N., Lutjohann D., Bayer T., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B. and Bjorkhem I. (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J. Lipid Res. 45, 186193.
  • Heverin M., Meaney S., Lutjohann D., Diczfalusy U., Wahren J. and Bjorkhem I. (2005) Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46, 10471052.
  • Hirsch-Reinshagen V., Zhou S. S., Burgess B. L., Bernier L., McIsaac S. A. and Chan J. Y. (2004) Deficiency of ABCA1 impairs apo E metabolism in brain. J. Biol. Chem. 279, 4119741207.
  • Hirsch-Reinshagen V., Maia L. F., Burgess B. L., Blain J. F., Naus K. E. and McIsaac S. A. (2005) The absence of ABCA1 decreases soluble apo E levels but does not diminish amyloid deposition in two murine models of Alzheimer’s disease. J. Biol. Chem. 280, 4324343256.
  • Hixson J. E., Vernier D. T. and Powers P. K. (1991) Detection of SstI restriction site polymorphism in human APOC3 by the polymerase chain reaction. Nucleic Acids Res. 19, 196.
  • Hofman A., Ott A., Breteler M. M., Bots M. L., Slooter A. J., Van Harskamp F., Van Duijn C. N., Van Broeckhoven C. and Grobbee D. E. (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 349, 151154.
  • Holtzman D. M., Bales K. R., Tenkova T. et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 97, 28922897.
  • Hone E., Martins I. J., Jeoung M., Ji T. H., Gandy S. E. and Martins R. N. (2005) Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J. Alzheimers Dis. 7, 303314.
  • Van‘t Hooft F. M., Ruotolo G., Boquist S., De Faire U., Eggertsen G. and Hamsten A. (2001) Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation 104, 12231228.
  • Horton J. D. and Shimomura I. (1999) Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol. 10, 143150.
  • Horton J. D., Bashmakov Y., Shimomura I. and Shimano H. (1998) Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl Acad. Sci. USA 95, 59875992.
  • Huang X., Atwood C. S., Hartshorn M. A. et al. (1999) The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 76097616.
  • Hutter-Paier B., Huttunen H. J., Puglielli L. et al. (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44, 227238.
  • Huttunen H. J., Greco C. and Kovacs D. M. (2007) Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett. 581, 16881692.
  • Huttunen H. J., Puglielli L., Ellis B. C., MacKenzie Ingano L. A. and Kovacs D. M. (2009) Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. J. Mol. Neurosci. 37, 615.
  • Im Y. J., Raychaudhuri S., Prinz W. A. and Hurley J. H. (2005) Structural mechanism for sterol sensing and transport by OSBP-related proteins. Nature 437, 154158.
  • Infante R. E., Abi-Mosleh L., Radhakrishnan A., Dale J. D., Brown M. S. and Goldstein J. L. (2008a) Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J. Biol. Chem. 283, 10521063.
  • Infante R. E., Radhakrishnan A., Abi-Mosleh L., Kinch L. N., Wang M. L., Grishin N. V., Goldstein J. L. and Brown M. S. (2008b) Purified NPC1 protein: II. Localization of sterol binding to a 240-amino acid soluble luminal loop. J. Biol. Chem. 283, 10641075.
  • Ito J., Zhang L. Y., Asai M. and Yokoyama S. (1999) Differential generation of high-density lipoprotein by endogenous and exogenous apolipoproteins in cultured fetal rat astrocytes. J. Neurochem. 72, 23622369.
  • Jaeger S. and Pietrzik C. U. (2008) Functional role of lipoprotein receptors in Alzheimer’s disease. Curr. Alzheimer Res. 5, 1525.
  • Jana A. and Pahan K. (2004) Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer’s disease. J. Biol. Chem. 279, 5145151459.
  • Janowski B. A., Willy P. J., Devi T. R., Falck J. R. and Mangelsdorf D. J. (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383, 728731.
  • Jarvik G. P., Austin M. A., Fabsitz R. R., Auwerx J., Reed T., Christian J. C. and Deeb S. (1994) Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects. Genet. Epidemiol. 11, 375384.
  • Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C. and Larson E. B. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case–control study. Neurology 45, 10921096.
  • Jellinger K. A. (2002) Alzheimer’s disease and cerebrovascular pathology: an update. J. Neural. Transm. 109, 813836.
  • Jian B., De La Llera-Moya M., Ji Y., Wang N., Phillips M. C., Swaney J. B., Tall A. R. and Rothblat G. H. (1998) Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J. Biol. Chem. 273, 55995606.
  • Jick H., Zornberg G. L., Jick S. S., Seshadri S. and Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 16271631.
  • Jonas A., Sweeny S. A. and Herbert P. N. (1984) Discoidal complexes of A and C apolipoproteins with lipids and their reactions with lecithin: cholesterol acyltransferase. J. Biol. Chem. 259, 63696375.
  • Kabbara A., Payet N., Cottel D., Frigard B., Amouyel P. and Lambert J. C. (2004) Exclusion of CYP46 and APOM as candidate genes for Alzheimer’s disease in a French population. Neurosci. Lett. 363, 139143.
  • Kaether C., Haass C. and Steiner H. (2006) Assembly, trafficking and function of gamma-secretase. Neurodegener. Dis. 3, 275283.
  • Kagan B., Hirakura Y., Azimov R., Azimova R. and Lin M. (2002) The channel hypothesis of Alzheimer’s disease: current status. Peptides 23, 13111315.
  • Kakio A., Nishimoto S. I., Yanagisawa K., Kozutsumi Y. and Matsuzaki K. (2001) Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, and endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276, 2498524990.
  • Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y. and Matsuzaki K. (2002) Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer’s amyloid. Biochemistry 41, 73857390.
  • Kakio A., Nishimoto S., Kozutsumi Y. and Matsuzaki Y. (2003) Formation of a membrane active form of amyloid beta protein in raft-like model membranes. Biochem. Biophys. Res. Comm. 303, 514518.
  • Kalaria R. (1996) Cerebral vessels in ageing and Alzheimer’s disease. Pharmacol. Ther. 72, 193214.
  • Kalaria R. (1999) The blood brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann. N Y Acad. Sci. 893, 113125.
  • Kalaria R. (2002) Small vessel disease and Alzheimer’s dementia: pathological considerations. Cerebrovasc. Dis. 2, 4852.
  • Kalaria R. (2003) Vascular factors in Alzheimer’s disease. Int. Psychogeriatr. 1, 4752.
  • Kalman J., McConathy W., Araoz C., Kasa P. and Lacko A. G. (2000) Apolipoprotein D in the aging brain and in Alzheimer’s dementia. Neurol. Res. 22, 330336.
  • Kamino K., Yoshiiwa A., Nishiwaki Y. et al. (1996) Genetic association study between senile dementia of Alzheimer’s type and APOE/C1/C2 gene cluster. Gerontology 42(Suppl. 1), 1219.
  • Kankaanpaa J., Turunen S. P., Moilanen V., Horkko S. and Remes A. M. (2009) Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer’s disease. Neurobiol. Dis. 33, 467472.
  • Kassner S. S., Bonaterra G. A., Kaiser E., Hildebrandt W., Metz J., Schroder J. and Kinscherf R. (2008) Novel systemic markers for patients with Alzheimer disease? – a pilot study. Curr. Alzheimer Res. 5, 358366.
  • Katsel P., Li C. and Haroutunian V. (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem. Res. 32, 845856.
  • Katzov H., Chalmers K., Palmgren J. et al. (2004) Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum. Mutat. 23, 358367.
  • Kawahara M. and Kuroda Y. (2000) Molecular mechanism of neurodegeneration induced by Alzheimer’s beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53, 389397.
  • Keller J. N., Hanni K. B. and Markesbery W. R. (1999) Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J. Neurochem. 72, 26012609.
  • Ki C. S., Na D. L., Kim D. K., Kim H. J. and Kim J. W. (2002) Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer’s disease. Neurosci. Lett. 319, 7578.
  • Kim H. J., Miyazaki M. and Ntambi J. M. (2002) Dietary cholesterol opposes PUFA-mediated repression of the stearoyl-CoA desaturase-1 gene by SREBP-1 independent mechanism. J. Lipid Res. 43, 17501757.
  • Kim W. S., Rahmanto A. S., Kamili A., Rye K. A., Guillemin G. J., Gelissen I. C., Jessup W., Hill A. F. and Garner B. (2007) Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J. Biol. Chem. 282, 28512861.
  • Kim W. S., Chan S. L., Hill A. F., Guillemin G. J. and Garner B. (2009) Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J. Alzheimers Dis. 16, 121131.
  • Kinnunen P. K. and Ehnolm C. (1976) Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 65, 354357.
  • Kivipelto M., Helkala E. L., Laakso M. P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J. and Nissinen A. (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322, 14471451.
  • Ko M. H. and Puglielli L. (2009) Two endoplasmic reticulum (ER)/ER Golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. J. Biol. Chem. 284, 24822492.
  • Koch S., Donarski N., Goetze K., Kreckel M., Stuerenberg H. J., Buhmann C. and Beisiegel U. (2001) Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42, 11431151.
  • Kojro E., Gimpl G., Lammich S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 58155820.
  • Koldamova R. P., Lefterov I. M., Ikonomovic M. D., Skoko J., Lefterov P. I. and Isanki B. A. (2003) 22R-Hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter AI expression and cholesterol efflux in brain cells and decrease amyloid secretion. J. Biol. Chem. 278, 1324413256.
  • Koldamova R., Staufenbiel M. and Lefterov I. (2005) Lack of ABCA1 considerably decreases brain apo E level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280, 4322443235.
  • Kolsch H., Lutjohann D., Ludwig M. et al. (2002) Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease. Mol. Psychiatry 7, 899902.
  • Kolsch H., Lutjohann D., Von Bergmann K. and Heun R. (2003) The role of 24S- hydroxycholesterol in Alzheimer’s disease. J. Nutr. Health Aging 7, 3741.
  • Kolsch H., Heun R., Kerksiek A., Bergmann K. V., Maier W. and Lutjohann D. (2004) Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 368, 303308.
  • Kontush A., Mann U., Arlt S., Ujeyl A., Luhrs C. and Muller-Thomsen T. (2001) Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer’s disease. Free Radic. Biol. Med. 31, 345354.
  • Koudinov A. R., Koudinova N. V., Kumar A., Beavis R. C. and Ghiso J. (1996) Biochemical characterization of Alzheimer’s soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun. 223, 592597.
  • Kracun I., Rosner H., Drnovsek V., Heffer-Lauc M., Cosovic C. and Lauc G. (1991) Human brain gangliosides in development, aging and disease. Int. J. Dev. Biol. 35, 289295.
  • Kracun I., Kalanj S., Talan-Hranilovic J. and Cosovic C. (1992) Cortical distribution of gangliosides in Alzheimer’s disease. Neurochem. Int. 20, 433438.
  • Kramer A. F., Colcombe S. J., McAuley E., Scalf P. E. and Erickson K. I. (2005) Fitness, aging and neurocognitive function. Neurobiol. Aging Suppl. 26, 124127.
  • Kujiraoka T., Hattori H., Miwa Y. et al. (2006) Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J. Atheroscler. Thromb. 13, 314322.
  • Kuo Y. M., Emmerling M. R., Bisgaier C. L., Essenburg A. D., Lampert H. C., Drumm D. and Roher A. E. (1998) Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain abeta 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711715.
  • Kwak J. W., Kim H. K. and Chae C. B. (2006) Potential lead for an Alzheimer drug: a peptide that blocks intermolecular interaction and amyloid beta protein-induced cytotoxicity. J. Med. Chem. 49, 48134817.
  • Kwon H. J., Abi-Mosleh L., Wang M. L., Deisenhofer J., Goldstein J. L., Brown M. S. and Infante R. E. (2009) Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137, 12131224.
  • LaDu M. J., Gilligan S. M., Lukens J. R., Cabana V. G., Reardon C. A., Van Eldik L. J. and Holtzman D. M. (1998) Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70, 20702081.
  • LaDu M. J., Reardon C., Eldik L. V., Fagan A. M., Bu G., Holtzman D. and Getz G. S. (2000) Lipoproteins in the central nervous system. Ann. N Y Acad. Sci. 903, 167175.
  • Lagrost L., Persegol L., Lallemant C. and Gambert P. (1994) Influence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and AII. J. Biol. Chem. 269, 31893197.
  • Laitinen S., Olkkonen V. M., Ehnholm C. and Ikonen E. (1999) Family of human oxysterol binding protein (OSBP) homologues. A novel member implicated in brain sterol metabolism. J. Lipid Res. 40, 22042211.
  • Lambert J. C., Luedecking-Zimmer E., Merrot S. et al. (2003) Association of 3′-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer’s disease. J. Med. Genet. 40, 424430.
  • LaRosa J. C., Levy R. I., Herbert P., Lux S. E. and Fredrickson D. S. (1970) A specific apoprotein activator for lipoprotein lipase. Biochem. Biophys. Res. Commun. 41, 5762.
  • Laufs U., Gertz K., Huang P., Nickenig G., Bohm M., Dirnagl U. and Endres M. (2000) Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31, 24422449.
  • Lawn R. M., Wade D. P., Couse T. L. and Wilcox J. N. (2001) Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler. Thromb. Vasc. Biol. 21, 378385.
  • Laws S. M., Hone E., Taddei K. et al. (2002) Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol. Psychiatry 7, 886890.
  • Lazarov O., Peterson L. D., Peterson D. A. and Sisodia S. S. (2006) Expression of a familial Alzheimer’s disease-linked presenilin-1 variant enhances perforant pathway lesion-induced neuronal loss in the entorhinal cortex. J. Neurosci. 26, 429434.
  • Le Jossic-Corcos C., Gonthier C., Zaghini I., Logette E., Shechter I. and Bournot P. (2005) Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids. Biochem. J. 385, 787794.
  • Ledesma M. D. and Dotti C. G. (2006) Amyloid excess in Alzheimer’s disease: what is cholesterol to be blamed for? FEBS Lett. 580, 55255532.
  • Ledesma M. D., Abad-Rodriguez J., Galvan C., Biondi E., Navarro P., Delacourte A., Dingwall C. and Dotti C. G. (2003) Raft disorganization leads to reduced plasmin activity in Alzheimer’s disease brains. EMBO Rep. 4, 11901196.
  • Lee S. J., Liyanage U., Bickel P. E., Xia W., Lansbury P. T. Jr and Kosik K. S. (1998) A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4, 730734.
  • Lee J. T., Xu J., Lee J. M., Ku G., Han X., Yang D. I., Chen S. and Hsu C. Y. (2004) Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 164, 123131.
  • Lehto M. and Olkkonen V. M. (2003) The OSBP-related proteins: a novel protein family involved in vesicle transport, cellular lipid metabolism, and cell signalling. Biochim. Biophys. Acta 1631, 111.
  • Leon C., Hill J. S. and Wasan K. M. (2005) Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res. 22, 15781588.
  • Lewis G. F. and Rader D. J. (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 12211232.
  • Liang Y., Lin S., Beyer T. P. et al. (2004) A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 88, 623634.
  • Lidstrom A. M., Bogdanovic N., Hesse C., Volkman I., Davidsson P. and Blennow K. (1998) Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. Exp. Neurol. 154, 511521.
  • Lin H., Bhatia R. and Lal R. (2001) Amyloid beta proteins forms ion channels: implications for Alzheimer’s disease pathophysiology. FASEB J. 15, 24332444.
  • Lindqvist P., Ostlund-Lindqvist A. M., Witztum J. L., Steinberg D. and Little J. A. (1983) The role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins by macrophages. J. Biol. Chem. 258, 90869092.
  • Linton M. F., Gish R., Hubl S. T., Butler E., Esquivel C., Bry W. I., Boyles J. K., Wardell M. R. and Young S. G. (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88, 270281.
  • Liu Q., Zerbinatti C. V., Zhang J., Hoe H. S., Wang B., Cole S. L., Herz J., Muglia L. and Bu G. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 6678.
  • Loscher W. and Potschka H. (2005) Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2, 8698.
  • Luedecking-Zimmer E., DeKosky S. T., Chen Q., Barmada M. M. and Kamboh M. I. (2002) Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer’s disease on chromosome 12. Hum. Genet. 111, 443451.
  • Lund E. G., Guileyardo J. M. and Russell D. W. (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. N Y Acad. Sci. 96, 72387243.
  • Lutjohann D. and Von Bergmann K. (2003) 24S-hydroxy cholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36, S102S106.
  • Lutjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden A., Diczfalusy U. and Bjorkhem I. (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl Acad. Sci. USA 93, 97999804.
  • Lutjohann D., Papassotiropoulos A., Bjorkhem I. et al. (2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41, 195198.
  • Mahley R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622630.
  • Malaplate-Armand C., Florent-Bechard S., Youssef I. et al. (2006) Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23, 178189.
  • Manelli A. M., Bulfinch L. C., Sullivan P. M. and LaDu M. J. (2007) Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol. Aging 28, 11391147.
  • Martel C. L., Mackic J. B., Matsubara E. et al. (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood–brain barrier transport of circulating Alzheimer’s amyloid beta. J. Neurochem. 69, 19952004.
  • Martins I., Sainsbury A., Mamo J. and Redgrave T. (1994) Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats. Diabetologia 37, 238246.
  • Marzal-Casacuberta A., Blanco-Vaca F., Ishida B. Y., Julve-Gil J., Shen J., Calvet-Marquez S., Gonzalez-Sastre F. and Chan L. (1996) Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J. Biol. Chem. 271, 67206728.
  • Marzolo M. P. and Bu G. (2009) Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer’s disease. Semin. Cell Dev. Biol. 20, 191200.
  • Mason R. P., Shoemaker W. J., Shajenko L., Chambers T. E. and Herbette L. G. (1992) Evidence for changes in the Alzheimer’s disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413419.
  • Matsuura E., Hughes G. R. and Khamashta M. A. (2008) Oxidation of LDL and its clinical implication. Autoimmun. Rev. 7, 558566.
  • May P., Rohlmann A., Bock H. H. et al. (2004) Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol. Cell. Biol. 24, 88728883.
  • McConathy W. J., Gesquiere J. C., Bass H., Tartar A., Fruchart J. C. and Wang C. S. (1992) Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. 33, 9951003.
  • Meaney S., Heverin M., Panzenboeck U. et al. (2007) Novel route for elimination of brain oxysterols across the blood–brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 48, 944951.
  • Van Meer G., Halter D., Sprong H., Somerharju P. and Egmond M. R. (2006) ABC lipid transporters: extruders, flippases, or flopless activators? FEBS Lett. 580, 11711177.
  • Merched A., Xia Y., Visvikis S., Serot J. M. and Siest G. (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol. Aging 21, 2730.
  • Metzger R. E., LaDu M. J., Pan J. B., Getz G. S., Frail D. E. and Falduto M. T. (1996) Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 55, 372380.
  • Michikawa M., Fan Q. W., Isobe I. and Yanagisawa K. (2000) Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74, 10081016.
  • Mielke M. M., Bandaru V. V., Haughey N. J., Rabins P. V., Lyketsos C. G. and Carlson M. C. (2008) Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol. Aging May 1. Epub ahead of print.
  • Miller L. J. and Chacko R. (2004) The role of cholesterol and statins in Alzheimer’s disease. Ann. Pharmacother. 38, 9198.
  • Miller K. W. and Small D. M. (1983) Surface to core and interparticle equilibrium distributions of triglyceride-rich and lipoprotein lipids. J. Biol. Chem. 258, 1377213784.
  • Miyazaki A., Kanome T. and Watanabe T. (2005) Inhibitors of acyl-coenzyme a: cholesterol acyltransferase. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5, 463469.
  • Mouchel Y., Lefrancois T., Fages C. and Tardy M. (1995) Apolipoprotein E gene expression in astrocytes: developmental pattern and regulation. Neuroreport 7, 205208.
  • Mufson E. J., Benzing W. C., Cole G. M., Wang H., Emerich D. F., Sladek J. J. R., Morrison J. H. and Kordower J. H. (1994) Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization with amyloid plaques. Neurobiol. Aging 15, 621627.
  • Mulder M., Blokland A., Van Den Berg D. J., Schulten H., Bakker A. H. and Terwell D. (2001) Apolipoprotein E protects against neuropathology induced by a high fat diet and maintains the integrity of the blood brain barrier during aging. Lab. Invest. 81, 953960.
  • Mullan M., Scibelli P., Duara R. et al. (1996) Familial and population-based studies of apolipoprotein E and Alzheimer’s disease. Ann. N Y Acad. Sci. 802, 1626.
  • Muse E. D., Jurevics H., Toews A. D., Matsushima G. K. and Morell P. (2001) Parameters related to lipid metabolism as markers of myelination in mouse brain. J. Neurochem. 76, 7786.
  • Nagy Z. (2005) The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer’s disease. J. Cell Mol. Med. 9, 531541.
  • Nakai M., Kawamata T., Taniguchi T., Maeda K. and Tanaka C. (1996) Expression of apolipoprotein E mRNA in rat microglia. Neurosci. Lett. 211, 4144.
  • Namba Y., Tomonaga M., Kawasaki H., Otomo E. and Ikeda K. (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163166.
  • Namba Y., Tsuchiya H. and Ikeda K. (1992) Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer’s disease. Neurosci. Lett. 134, 264266.
  • Narita M., Bu G., Holtzman D. M. and Schwartz A. L. (1997) The low-density lipoprotein receptor-related protein, a multifunctional apolipoprotein E receptor, modulates hippocampal neurite development. J. Neurochem. 68, 587595.
  • Navab M., Hama-Levy S., Van Lenten B. J. et al. (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio [published erratum appears in J Clin Invest 1997 Jun 15;99(12):3043]. J. Clin. Invest. 99, 20052019.
  • Navarro A., Del Valle E., Astudillo A., Gonzalez del Rey C. and Tolivia J. (2003) Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral [beta] amyloid deposits. Exp. Neurol. 184, 697704.
  • Neely M. D. and Montine T. J. (2002) CSF lipoproteins and Alzheimer’s disease. J. Nutr. Health Aging 6, 383391.
  • Nelson T. J. and Alkon D. L. (2005) Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 280, 73777387.
  • Nelson T. J. and Alkon D. L. (2007) Protection against beta-amyloid-induced apoptosis by peptides interacting with beta-amyloid. J. Biol. Chem. 282, 3123831249.
  • Notkola I. L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J. and Nissinen A. (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 17, 1420.
  • Ogura T., Mio K., Hayashi I. et al. (2006) Three-dimensional structure of the gamma-secretase complex. Biochem. Biophys. Res. Commun. 343, 525534.
  • Ohm T. G., Treiber-Held S., Distl R., Glockner F., Schonheit B., Tamanai M. and Meske V. (2003) Cholesterol and tau protein – findings in Alzheimer’s and Niemann Pick C’s disease. Pharmacopsychiatry 36, S120S126.
  • Olivieri O., Stranieri C., Bassi A. et al. (2002) ApoC-III gene polymorphisms and risk of coronary artery disease. J. Lipid Res. 43, 14501457.
  • Olkkonen V. M. and Lehto M. (2004) Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis. Ann. Med. 36, 562572.
  • Op Den Velde W. and Hooghwinkel G. J. (1975) The brain ganglioside pattern in presenile and senile dementia. J. Am. Geriatr. Soc. 23, 301303.
  • Oram J. F. and Heinecke J. W. (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85, 13431372.
  • Osawa S., Funamoto S., Nobuhara M., Wada-Kakuda S., Shimojo M., Yagishita S. and Ihara Y. (2008) Phosphoinositides suppress gamma-secretase in both the detergent-soluble and -insoluble states. J. Biol. Chem. 283, 1928319292.
  • Ostrowski S. M., Wilkinson B. L., Golde T. E. and Landreth G. (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J. Biol. Chem. 282, 2683226844.
  • Ott A., Breteler M. M., De Bruyne M. C., Van Harskamp F., Grobbee D. E. and Hofman A. (1997) Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28, 316321.
  • Pan W., Kastin A. J., Zankel T. C., Van Kerkhof P., Terasaki T. and Bu G. (2004) Efficient transfer of receptor-associated protein (RAP) across the blood–brain barrier. J. Cell Sci. 117, 50715078.
  • Panzenboeck U., Balazs Z., Sovic A., Hrzenjak A., Levak-Frank S., Wintersperger A., Malle E. and Sattler W. (2002) ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood–brain barrier constituted of porcine brain capillary endothelial cells. J. Biol. Chem. 277, 4278142789.
  • Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli M., Jessen F. and Rao M. L. (2000) Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease. Neuroreport 11, 19591962.
  • Papassotiropoulos A., Lutjohann D., Bagli M. et al. (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 2732.
  • Papassotiropoulos A., Streffer J. R., Tsolaki M. et al. (2003) Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60, 2935.
  • Pappolla M. A., Bryant-Thomas T. K., Herbert D. et al. (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199205.
  • Paradis E., Clavel S., Julien P., Murthy M. R., De Bilbao F., Arsenijevic D., Giannakopoulos P., Vallet P. and Richard D. (2004) Lipoprotein lipase and endothelial lipase expression in mouse brain: regional distribution and selective induction following kainic acid-induced lesion and focal cerebral ischemia. Neurobiol Dis 15, 312325.
  • Parks A. L. and Curtis D. (2007) Presenilin diversifies its portfolio. Trends Genet. 23, 140150.
  • Parra H. J., Arveiler D., Evans A. E. et al. (1992) A case–control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler. Thromb. 12, 701707.
  • Patel N. V. and Finch C. E. (2002) The glucocorticoid paradox of caloric restriction in slowing brain aging. Neurobiol. Aging 23, 707717.
  • Perry R. J. and Ridgway N. D. (2006) Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. Mol. Biol. Cell 17, 26042616.
  • Petanceska S. S., DeRosa S., Olm V., Diaz N., Sharma A., Thomas-Bryant T., Duff K., Pappolla M. and Refolo L. M. (2002) Statin therapy for Alzheimer’s disease: will it work? J. Mol. Neurosci. 19, 155161.
  • Petit-Turcotte C., Stohl S. M., Beffert U. et al. (2001) Apolipoprotein C-I Expression in the Brain in Alzheimer’s Disease. Neurobiol. Dis. 8, 953963.
  • Pfrieger F. W. (2003) Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60, 11581171.
  • Pillot T., Goethals M., Najib J., Labeur C., Lins L., Chambaz J., Brasseur R., Vandekerckhove J. and Rosseneu M. (1999) Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer’s disease. J. Neurochem. 72, 230237.
  • Pilon A., Briand O., Lestavel S., Copin C., Majd Z., Fruchart J. C., Castro G. and Clavey V. (2000) Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake. Arterioscler. Thromb. Vasc. Biol. 20, 10741081.
  • Pitas R. E., Boyles J. K., Lee S. H., Hui D. and Weisgraber K. H. (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262, 1435214360.
  • Poduslo S. E., Neal M. and Schwankhaus J. (1995) A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer’s disease. Neurosci. Lett. 201, 8183.
  • Poduslo S. E., Neal M., Herring K. and Shelly J. (1998) The apolipoprotein CI A allele as a risk factor for Alzheimer’s disease. Neurochem. Res. 23, 361367.
  • Poirier J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci. 17, 525530.
  • Poirier J. (2000) Apolipoprotein E and Alzheimer’s disease. A role in amyloid catabolism. Ann. N Y Acad. Sci. 924, 8190.
  • Poirier J. (2005) Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer’s disease. Neurobiol. Aging 26, 355361.
  • Poirier J., Hess M., May P. C. and Finch C. E. (1991) Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 11, 97106.
  • Poirier J., Bertrand P., Poirier J. et al. (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342, 697699.
  • Polavarapu R., An J., Zhang C. and Yepes M. (2008) Regulated intramembrane proteolysis of the low-density lipoprotein receptor-related protein mediates ischemic cell death. Am. J. Pathol. 172, 13551362.
  • Prasanthi J. R., Huls A., Thomasson S., Thompson A., Schommer E. and Ghribi O. (2009) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 4, 1.
  • Puglielli L., Konopka G., Pack-Chung E., Ingano L. A., Berezovska O., Hyman B. T., Chang T. Y., Tanzi R. E. and Kovacs D. M. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3, 905912.
  • Puglielli L., Ellis B. C., Ingano L. A. and Kovacs D. M. (2004) Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein. J. Mol. Neurosci. 24, 9396.
  • Puglielli L., Friedlich A. L., Setchell K. D. et al. (2005) Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J. Clin. Invest. 115, 25562563.
  • Pussinen P. J., Jauhiainen M. and Ehnholm C. (1997) ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. J. Lipid Res. 38, 1221.
  • Qureischie H., Heun R., Lutjohann D. et al. (2008) CETP polymorphisms influence cholesterol metabolism but not Alzheimer’s disease risk. Brain Res. 1232, 16.
  • Racchi M., Baetta R., Salvietti N. et al. (1997) Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem. J. 322, 893898.
  • Raffai R. L. and Weisgraber K. H. (2003) Cholesterol: from heart attacks to Alzheimer’s disease. J. Lipid Res. 44, 14231430.
  • Rapp A., Gmeiner B. and Huttinger M. (2006) Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88, 473483.
  • Rassart E., Bedirian A., Do Carmo S., Guinard O., Sirois J., Terrisse L. and Milne R. (2000) Apolipoprotein D. Biochem. Biophys. Acta 1482, 185198.
  • Rebeck G. (2004) Cholesterol efflux as a critical component of Alzheimer’s disease pathogenesis. J. Mol. Neurosci. 23, 219224.
  • Rebeck G. W., Reiter J. S., Strickland D. K. and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11, 575580.
  • Van Ree J. H., Van Den Broek W. J., Van Der Zee A., Dahlmans V. E., Wieringa B., Frants R. R., Havekes L. M. and Hofker M. H. (1995) Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. Hum. Mol. Genet. 4, 14031409.
  • Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K. and Pappolla M. A. (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321331.
  • Refolo L. M., Pappolla M. A., LaFrancois J. et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 8, 890899.
  • Reid P. C., Urano Y., Kodama T. and Hamakubo T. (2007) Alzheimer’s disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell Mol. Med. 11, 383392.
  • Retz W., Thome J., Durany N., Harsanyi A., Retz-Junginger P., Kornhuber J., Riederer P. and Rosler M. (2001) Potential genetic markers of sporadic Alzheimer’s dementia. Psychiatr. Genet. 11, 115122.
  • Rhodin J. A. and Thomas T. (2001) A vascular connection to Alzheimer’s disease. Microcirculation 8, 207220.
  • Rodriguez E., Mateo I., Infante J., Llorca J., Berciano J. and Combarros O. (2006) Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer’s disease risk associated with APOE epsilon4 allele. J. Neurol. 253, 181185.
  • Roher A. E., Kuo Y. M., Kokjohn K. M., Emmerling M. R. and Gracon S. (1999) Amyloid and lipids in the pathology of Alzheimer’s disease. Amyloid 6, 136145.
  • Rosenberg M. E., Dvergsten J. and Correa-Rotter R. (1993) Clusterin: an enigmatic protein recruited by diverse stimuli. J. Lab. Clin. Med. 121, 205214.
  • Ruitenberg A., Den Heijer T., Bakker S. L., Van Swieten J. C., Koudstaal P. J., Hofman A. and Breteler M. M. (2005) Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 57, 789794.
  • Runz H., Rietdorf J., Tomic I., De Bernard M., Beyreuther K., Pepperkok R. and Hartmann T. (2002) Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22, 16791689.
  • Sacher J., Weigl L., Werner M., Szegedi C. and Hohenegger M. (2005) Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J. Pharmacol. Exp. Ther. 314, 10321041.
  • Saczynski J. S., White L., Peila R. L., Rodriguez B. L. and Launer L. J. (2007) The relation between apolipoprotein A-I and dementia: the Honolulu–Asia aging study. Am. J. Epidemiol. 165, 985992.
  • Sadowski M., Pankiewicz J., Scholtzova H., Li Y. S., Quartermain D., Duff K. and Wisniewski T. (2004) Links between the pathology of Alzheimer’s disease and vascular dementia. Neurochem. Res. 29, 12571266.
  • Saher G., Brugger B., Lappe-Siefke C., Mobius W., Tozawa R., Wehr M. C., Wieland F., Ishibashi S. and Nave K. A. (2005) High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8, 468475.
  • Salminen A., Ojala J., Suuronen T., Kaarniranta K. and Kauppinen A. (2008) Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer’s pathology. J. Cell Mol. Med. 12, 22552262.
  • Scacchi R., Gambina G., Ruggeri M., Martini M. C., Ferrari G., Silvestri M., Schiavon R. and Corbo R. M. (1999) Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer’s disease. Neurosci. Lett. 259, 3336.
  • Scalco M. Z. and Van Reekum R. (2006) Prevention of Alzheimer disease. Encouraging evidence. Can. Fam. Physician 52, 200207.
  • Schaefer E. J., Anderson D. W., Zech L. A., Lindgren F. T., Bronzert T. B., Rubalcaba E. A. and Brewer H. B. Jr (1981) Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J. Lipid Res. 22, 217228.
  • Schneider A., Schulz-Schaeffer W., Hartmann T., Schulz J. B. and Simons M. (2006) Cholesterol depletion reduces the aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol. Dis. 23, 573577.
  • Schoonjans K., Peinado-Onsurbe J., Fruchart J. C., Tailleux A., Fievet C. and Auwerx J. (1999) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452, 160164.
  • Schroepfer G. J. Jr (2000) Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80, 361554.
  • Schultz J. R., Gong E. L., McCall M. R., Nichols A. V., Clift S. M. and Rubin E. M. (1992) Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J. Biol. Chem. 267, 2163021636.
  • Schultz J. R., Verstuyft J. G., Gong E. L., Nichols A. V. and Rubin E. M. (1993) Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 365, 762764.
  • Shachter N. S. (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12, 297304.
  • Shen B. W., Scanu A. M. and Kezdy F. J. (1977) Structure of human serum lipoproteins inferred from compositional analysis. Proc. Natl Acad. Sci. USA 74, 837841.
  • Shi J., Tian J., Pritchard A., Lendon C., Lambert J. C., Iwatsubo T. and Mann D. M. (2006) A 3′-UTR polymorphism in the oxidized LDL receptor 1 gene increases Abeta40 load as cerebral amyloid angiopathy in Alzheimer’s disease. Acta Neuropathol. 111, 1520.
  • Shibata M., Yamada S., Kumar S. R. et al. (2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest. 106, 14891499.
  • Shie F. S., Jin L. W., Cook D. G., Leverenz J. B. and LeBoeuf R. C. (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13, 455459.
  • Shobab L. A., Hsiung G. Y. R. and Feldman H. H. (2005) Cholesterol in Alzheimer’s disease. Lancet Neurol. 4, 841852.
  • Shusta E. V. (2005) Blood–brain barrier genomics, proteomics, and new transporter discovery. NeuroRx 2, 151161.
  • Sidera C., Parsons R. and Austen B. (2005) The regulation of beta-secretase by cholesterol and statins in Alzheimer’s disease. J. Neurol. Sci. 229–230, 269273.
  • De Silva H. V., Harmony J. A., Stuart W. D., Gil C. M. and Robbins J. (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29, 53805389.
  • Simakova O. and Arispe N. J. (2006) Early and late cytotoxic effects of external application of the Alzheimer’s Abeta result from the initial formation and function of Abeta ion channels. Biochemistry 45, 59075915.
  • Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G. and Simons K. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 64606464.
  • Sinensky M. (1977) Isolation of a mammalian cell mutant resistant to 25-hydroxy cholesterol. Biochem. Biophys. Res. Commun. 78, 863867.
  • Small D. H. (2009) Dysregulation of calcium homeostasis in Alzheimer’s disease. Neurochem. Res. 34, 1824–1829.
  • Small S. A. and Duff K. (2008) Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron 60, 534542.
  • Smit M., Van Der Kooij-Meijs E., Frants R. R., Havekes L. and Klasen E. C. (1988) Apolipoprotein gene cluster on chromosome 19. Definite localization of the APOC2 gene and the polymorphic Hpa I site associated with type III hyperlipoproteinemia. Hum. Genet. 78, 9093.
  • Smith C. C., Stanyer L., Betteridge D. J. and Cooper M. B. (2007) Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble beta-amyloid peptides in rat aorta. Clin. Sci. (Lond) 113, 427434.
  • Snipes G. J. and Suter U. (1997) Cholesterol and myelin. Subcell. Biochem. 28, 173204.
  • Snowdon D. A. (1997) Aging and Alzheimer’s disease: lessons from the Nun Study. Gerontologist 37, 150156.
  • Soundararajan R., Wishart A. D., Rupasinghe H. P., Arcellana-Panlilio M., Nelson C. M., Mayne M. and Robertson G. S. (2008) Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells in vitro against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. J. Biol. Chem. 283, 22312245.
  • Soutar A. K., Garner C. W., Baker H. N., Sparrow J. T., Jackson R. L., Gotto A. M. and Smith L. C. (1975) Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 14, 30573064.
  • Sovic A., Panzenboeck U., Wintersperger A. et al. (2005) Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood–brain barrier. J. Neurochem. 94, 109119.
  • Sparks D. L., Martin T. A., Gross D. R. and Hunsaker J. C. 3rd (2000) Link between heart disease, cholesterol, and Alzheimer’s disease: a review. Microsc. Res. Tech. 50, 287290.
  • Sparks D. L., Lopez J., Connor D., Sabbagh M., Seward J. and Browne P. (2003) A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer’s Disease Cholesterol-Lowering Treatment Trial (ADCLT). J. Mol. Neurosci. 20, 407410.
  • Sparks D. L., Petanceska S., Sabbagh M. et al. (2005a) Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr. Alzheimer Res. 2, 527539.
  • Sparks D. L., Sabbagh M. N., Connor D. J. et al. (2005b) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62, 753757.
  • Sparks D. L., Sabbagh M. N., Connor D. J. et al. (2005c) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res. 2, 343353.
  • Spell C., Kolsch H., Lutjohann D., Kerksiek A., Hentschel F. and Damian M. (2004) SREBP-1a Polymorphism influences the risk of Alzhiemer’s disease in carriers of the apo E4 allele. Dementia 18, 245249.
  • Stamatakis K., Cernuda-Morollon E., Hernandez-Perera O. and Perez-Sala D. (2002) Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway. J. Biol. Chem. 277, 4938949396.
  • Stefani M. and Liguri G. (2009) Cholesterol in Alzheimer’s disease: unresolved questions. Curr. Alzheimer Res. 6, 1529.
  • Steinberg D. (1997) Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272, 2096320966.
  • Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Hajian H. and Finch C. E. (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143, 313318.
  • Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S. and Roses A. D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 19771981.
  • Suchanek M., Hynynen R., Wohlfahrt G., Lehto M., Johansson M., Saarinen H., Radzikowska A., Thiele C. and Olkkonen V. M. (2007) The mammalian oxysterol-binding protein-related proteins (ORPs) bind 25-hydroxycholesterol in an evolutionarily conserved pocket. Biochem. J. 405, 473480.
  • Sun Y., Shi J., Zhang S., Tang M., Han H., Guo Y., Ma C., Liu X. and Li T. (2005) The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer’s disease in a Chinese population. Neurosci. Lett. 380, 219222.
  • Taddei K., Laws S. M., Verdile G. et al. (2008) Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiol. Aging 8, 8.
  • Takechi R., Galloway S., Pallebage-Gamarallage M., Wellington C., Johnsen R. and Mamo J. C. (2009) Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. Histochem. Cell Biol. 131, 661666.
  • Tam S. P. and Ramharack R. (1992) The effect of 25-hydroxycholesterol on the regulation of apolipoprotein E mRNA levels and secretion in the human hepatoma HepG2. Atherosclerosis 95, 137146.
  • Tam S. P., Mok L., Chimini G., Vasa M. and Deeley R. G. (2006) ABCA1 mediates high-affinity uptake of 25-hydroxycholesterol by membrane vesicles and rapid efflux of oxysterol by intact cells. Am. J. Physiol. Cell Physiol. 291, C490C502.
  • Tamamizu-Kato S., Cohen J. K., Drake C. B., Kosaraju M. G., Drury J. and Narayanaswami V. (2008) Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E. Biochemistry 47, 52255234.
  • Tamboli I. Y., Prager K., Barth E., Heneka M., Sandhoff K. and Walter J. (2005) Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280, 2811028117.
  • Tansley G. H., Burgess B. L., Bryan M. T. et al. (2007) The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J. Lipid Res. 48, 10221034.
  • Tarr P. T. and Edwards P. A. (2008) ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J. Lipid Res. 49, 169182.
  • Terrisse L., Poirier J., Bertrand P., Merched A., Visvikis S., Siest G., Milne R. and Rassart E. (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer’s patients. J. Neurochem. 71, 16431650.
  • Thomas E. A., Dean B., Pavey G. and Sutcliffe J. G. (2001a) Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc. Natl Acad. Sci. USA 98, 40664071.
  • Thomas E. A., Sautkulis L. N., Criado J. R., Games D. and Sutcliffe J. G. (2001b) Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice. J. Neurochem. 79, 10591064.
  • Thomas E. A., Dean B., Scarr E., Copolov D. and Sutcliffe J. G. (2003a) Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder. Mol. Psychiatry 8, 167175.
  • Thomas E. A., Laws S. M., Sutcliffe J. G. et al. (2003b) Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer’s disease: no relation to apolipoprotein E expression or genotype. Biol. Psychiatry 54, 136141.
  • Tokuda T., Calero M., Matsubara E. et al. (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem. J. 348, 359365.
  • Tomiyama T., Corder E. H. and Mori H. (1999) Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer’s disease. Cell. Mol. Life Sci. 56, 268279.
  • Trousson A., Bernard S., Petit P. X. et al. (2009) 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR. J. Neurochem. 109, 945958.
  • Tysoe C., Galinsky D., Robinson D., Brayne C., Huppert F. A., Dening T., Paykel E. S., Easton D. F. and Rubinsztein D. C. (1998) Apo E and Apo CI loci are associated with dementia in younger but not older late-onset cases. Dement. Geriatr. Cogn. Disord. 9, 191198.
  • Uehara Y., Yamada T., Baba Y., Miura S., Abe S., Kitajima K., Higuchi M. A., Iwamoto T. and Saku K. (2008) ATP-binding cassette transporter G4 is highly expressed in microglia in Alzheimer’s brain. Brain Res. 1217, 239246.
  • Urano Y., Hayashi I., Isoo N. et al. (2005) Association of active gamma-secretase complex with lipid rafts. J. Lipid Res. 46, 904912.
  • Valastyan S., Thakur V., Johnson A., Kumar K. and Manor D. (2008) Novel transcriptional activities of vitamin E: inhibition of cholesterol biosynthesis. Biochemistry 47, 744752.
  • Del Valle E., Navarro A., Astudillo A. and Tolivia J. (2003) Apolipoprotein D expression in human brain reactive astrocytes. J. Histochem. Cytochem. 51, 12851290.
  • Vance J. E., Hayashi H. and Karten B. (2005) Cholesterol homeostasis in neurons and glial cells. Semin. Cell Dev. Biol. 16, 193212.
  • Vaughan C. J., Murphy M. B. and Buckley B. M. (1996) Statins do more than just lower cholesterol. Lancet 348, 10791082.
  • Vaya J. and Schipper H. M. (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem. 102, 17271737.
  • Vega G. L., Weiner M. F., Lipton A. M., Von Bergmann K., Lutjohann D., Moore C. and Svetlik D. (2003) Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60, 510515.
  • Verd J. C., Peris C., Alegret M., Diaz C., Hernandez G., Vazquez M., Adzet T., Laguna J. C. and Sanchez R. M. (1999) Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br. J. Pharmacol. 127, 14791485.
  • Verdier Y. and Penke B. (2004) Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer’s disease. Curr. Protein Pept. Sci. 5, 1931.
  • Verdile G., Fuller S., Atwood C. S., Laws S. M., Gandy S. E. and Martins R. N. (2004) The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught? Pharmacol. Res. 50, 397409.
  • Verdile G., Gandy S. E. and Martins R. N. (2007) The role of presenilin and its interacting proteins in the biogenesis of Alzheimer’s beta amyloid. Neurochem. Res. 32, 609623.
  • Vetrivel K. S., Cheng H., Kim S. H., Chen Y., Barnes N. Y., Parent A. T., Sisodia S. S. and Thinakaran G. (2005) Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J. Biol. Chem. 280, 2589225900.
  • Vuletic S., Jin L. W., Marcovina S. M., Peskind E. R., Moller T. and Albers J. J. (2003) Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, increased levels in Alzheimer’s disease. J. Lipid Res. 44, 11131123.
  • Vuletic S., Peskind E. R., Marcovina S. M., Quinn J. F., Cheung M. C. and Kennedy H. (2005) Reduced CSF PLTP activity in Alzheimer’s disease and other neurologic diseases; PLTP induces apo E secretion in primary human astrocytes in vitro. J. Neurosci. Res. 80, 406413.
  • Wahrle S., Das P., Nyborg A. C., McLendon C., Shoji M., Kawarabayashi T., Younkin L. H., Younkin S. G. and Golde T. E. (2002) Cholesterol-dependent [gamma]-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 1123.
  • Wahrle S. E., Jiang H., Parsadanian M., Hartman R. E., Bales K. R., Paul S. M. and Holtzman D. M. (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 4323643242.
  • Wahrle S. E., Jiang H., Parsadanian M. et al. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671682.
  • Waldron E., Jaeger S. and Pietrzik C. U. (2006) Functional role of the low-density lipoprotein receptor-related protein in Alzheimer’s disease. Neurodegener. Dis. 3, 233238.
  • Walsh D. M., Klyubin I., Fadeeva J. V., Rowan M. J. and Selkoe D. J. (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552557.
  • Wang C. S., McConathy W. J., Kloer H. U. and Alaupovic P. (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75, 384390.
  • Wang N., Yvan-Charvet L., Lutjohann D., Mulder M., Vanmierlo T., Kim T. W. and Tall A. R. (2008a) ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J. 22, 10731082.
  • Wang Y., Muneton S., Sjovall J., Jovanovic J. N. and Griffiths W. J. (2008b) The effect of 24S-hydroxycholesterol on cholesterol homeostasis in neurons: quantitative changes to the cortical neuron proteome. J. Proteome Res. 7, 16061614.
  • Warden C. H., Langner C. A., Gordon J. I., Taylor B. A., McLean J. W. and Lusis A. J. (1989) Tissue-specific expression, developmental regulation, and chromosomal mapping of the lecithin: cholesterol acyltransferase gene. Evidence for expression in brain and testes as well as liver. J. Biol. Chem. 264, 2157321581.
  • Warden C. H., Hedrick C. C., Qiao J. H., Castellani L. W. and Lusis A. J. (1993) Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 261, 469472.
  • Wellington C. L., Walker E. K., Suarez A. et al. (2002) ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Invest. 82, 273283.
  • Weng W. and Breslow J. L. (1996) Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl Acad. Sci. USA 93, 1478814794.
  • Weng W., Brandenburg N. A., Zhong S., Halkias J., Wu L., Jiang X. C., Tall A. and Breslow J. L. (1999) ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice. J. Lipid Res. 40, 10641070.
  • Wisniewski T. and Frangione B. (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135, 235238.
  • Wollmer M. A., Streffer J. R., Tsolaki M., Grimaldi L. M., Lutjohann D. and Thal D. (2003) Genetic association of acyl-conenzyme A:cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and the risk for Alzheimer’s disease. Mol. Psychiatry 8, 635638.
  • Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 14391443.
  • Wolozin B., Wang S. W., Li N. C., Lee A., Lee T. A. and Kazis L. E. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 5, 20.
  • Wong J., Quinn C. M., Gelissen I. C. and Brown A. J. (2008) Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 283, 700707.
  • Worgall T. S., Sturley S. L., Seo T., Osborne T. F. and Deckelbaum R. J. (1998) Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein. J. Biol. Chem. 273, 2553725540.
  • Xie C., Lund E. G., Turley S. D., Russell D. W. and Dietschy J. M. (2003) Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J. Lipid Res. 44, 17801789.
  • Xu P. T., Gilbert J. R., Qiu H. L., Ervin J., Rothrock-Christian T. R., Hulette C. and Schmechel D. E. (1999) Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol. 154, 601611.
  • Xu J., Teran-Garcia M., Park J. H., Nakamura M. T. and Clarke S. D. (2001) Polyunsaturated fatty acids suppress hepatic sterol regulatory element-binding protein-1 expression by accelerating transcript decay. J. Biol. Chem. 276, 98009807.
  • Yamada T., Kawata M., Arai H., Fukasawa M., Inoue K. and Sato T. (1995) Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer’s disease brain tissues. Acta Neuropathol. (Berl) 90, 633636.
  • Yamagata K., Urakami K., Ikeda K., Ji Y., Adachi Y., Arai H., Sasaki H., Sato K. and Nakashima K. (2001) High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 12, 5762.
  • Yanagisawa K. and Matsuzaki K. (2002) Cholesterol-dependent aggregation of amyloid {beta}-protein. Ann. N Y Acad. Sci. 977, 384386.
  • Yepes M., Sandkvist M., Moore E. G., Bugge T. H., Strickland D. K. and Lawrence D. A. (2003) Tissue-type plasminogen activator induces opening of the blood–brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 15331540.
  • Yerbury J. J., Poon S., Meehan S., Thompson B., Kumita J. R., Dobson C. M. and Wilson M. R. (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21, 23122322.
  • Yu L., Von Bergmann K., Lutjohann D., Hobbs H. H. and Cohen J. C. (2004) Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J. Lipid Res. 45, 301307.
  • Zamrini E., McGwin G. and Roseman J. M. (2004) Association between statin use and Alzheimer’s disease. Neuroepidemiology 23, 9498.
  • Zannis V. I., Just P. W. and Breslow J. L. (1981) Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet. 33, 1124.
  • Zelcer N. and Tontonoz P. (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116, 607614.
  • Zerbinatti C. V., Wahrle S. E., Kim H., Cam J. A., Bales K., Paul S. M., Holtzman D. M. and Bu G. (2006) Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J. Biol. Chem. 281, 3618036186.
  • Zerbinatti C. V., Cordy J. M., Chen C. D., Guillily M., Suon S., Ray W. J., Seabrook G. R., Abraham C. R. and Wolozin B. (2008) Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. Mol. Neurodegener. 3, 5.
  • Zha Q., Ruan Y., Hartmann T., Beyreuther K. and Zhang D. (2004) GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 9, 946952.
  • Zhang J., Xue Y., Jondal M. and Sjovall J. (1997) 7alpha-Hydroxylation and 3-dehydrogenation abolish the ability of 25-hydroxycholesterol and 27-hydroxycholesterol to induce apoptosis in thymocytes. Eur. J. Biochem. 247, 129135.
  • Zhong S., Goldberg I. J., Bruce C., Rubin E., Breslow J. L. and Tall A. (1994) Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J. Clin. Invest. 94, 24572467.
  • Zhou Y., Suram A., Venugopal C., Prakasam A., Lin S., Su Y., Li B., Paul S. M. and Sambamurti K. (2008) Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. FASEB J. 22, 4754.
  • Zlokovic B. V., Martel C. L., Mackic J. B., Matsubara E., Wisniewski T., McComb J. G., Frangione B. and Ghiso J. (1994) Brain uptake of circulating apolipoproteins J and E complexed to alzheimer’s amyloid [beta]. Biochem. Biophys. Res. Comm. 205, 14311437.
  • Zlovkovic B. (2002) Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets. Adv. Drug Deliv. Rev. 54, 15331559.